Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy
Background: The 2018 American Society of Clinical Oncology/College of American Pathologists guidelines classified immunohistochemistry (IHC) 1+ or 2+, FISH-negative breast cancer as HER2-low. To date, only a few studies have investigated the role of HER2-low status in patients with hormone receptor...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2025-05-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/patterns-of-treatment-and-outcomes-of-patients-with-metastatic-her2-low-breast-cancer-treated-with-cdk4-6-inhibitors-and-hormone-therapy/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849313926996557824 |
|---|---|
| author | Federico Sottotetti Barbara Tagliaferri Gianpiero Rizzo Raffaella Palumbo Giulia Chessa Chiara Raso Lorenzo Perrone Alberto Malovini Valentina Tibollo Laura Deborah Locati Paolo Pedrazzoli Angioletta Lasagna |
| author_facet | Federico Sottotetti Barbara Tagliaferri Gianpiero Rizzo Raffaella Palumbo Giulia Chessa Chiara Raso Lorenzo Perrone Alberto Malovini Valentina Tibollo Laura Deborah Locati Paolo Pedrazzoli Angioletta Lasagna |
| author_sort | Federico Sottotetti |
| collection | DOAJ |
| description | Background: The 2018 American Society of Clinical Oncology/College of American Pathologists guidelines classified immunohistochemistry (IHC) 1+ or 2+, FISH-negative breast cancer as HER2-low. To date, only a few studies have investigated the role of HER2-low status in patients with hormone receptor positive/HER2– (HR+/HER2–) metastatic breast cancer (MBC) during CDK4/6 inhibitor (CDK4/6i) therapy.
Methods: This is a multicentre, retrospective cohort study analysing data from patients with HR+/HER2-low and HR+/HER2-0 MBC treated with CDK4/6i as first-line or second-line therapy at the Oncology Units of IRCCS San Matteo Hospital and ICS Maugeri IRCCS in Pavia, Italy, from January 2017 to October 2023. The aim was to assess the activity and effectiveness of CDK4/6i in a real-life setting.
Results: Of the 241 patients included, 240 (99.6%) were women. The median age at diagnosis was 57 years (IQR 48–65 years). Most patients had pM M0 (70.5%). At presentation, 112 (46.5%) had HER2-low and 129 (53.5%) had HER2-0 status. CDK4/6i were administered as first-line therapy in 89.2% of patients and as second-line therapy in 10.8% of patients, with palbociclib (61.4%) being the most common. The median progression-free survival during CDK4/6i therapy was 36.3 months (95% CI 23.6 months to not reached), while the median overall survival was 60.5 months (95% CI 54.4 months to not reached). Progression-free survival differed significantly between palbociclib and abemaciclib/ribociclib (24.4 versus 53.7 months; p=0.0109) and between first-line and second-line therapy (40.5 versus 21.2 months; p=0.0466).
Conclusion: CDK4/6i are effective in both HER2-low and HER2-0 MBC, with HER2-low potentially benefiting more from first-line therapy. |
| format | Article |
| id | doaj-art-7f8d11e5ffa5461dbee63bdcc932132d |
| institution | Kabale University |
| issn | 1740-4398 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BioExcel Publishing Ltd |
| record_format | Article |
| series | Drugs in Context |
| spelling | doaj-art-7f8d11e5ffa5461dbee63bdcc932132d2025-08-20T03:52:38ZengBioExcel Publishing LtdDrugs in Context1740-43982025-05-011411410.7573/dic.2024-12-1Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapyFederico SottotettiBarbara TagliaferriGianpiero RizzoRaffaella PalumboGiulia ChessaChiara RasoLorenzo PerroneAlberto MaloviniValentina TibolloLaura Deborah LocatiPaolo PedrazzoliAngioletta LasagnaBackground: The 2018 American Society of Clinical Oncology/College of American Pathologists guidelines classified immunohistochemistry (IHC) 1+ or 2+, FISH-negative breast cancer as HER2-low. To date, only a few studies have investigated the role of HER2-low status in patients with hormone receptor positive/HER2– (HR+/HER2–) metastatic breast cancer (MBC) during CDK4/6 inhibitor (CDK4/6i) therapy. Methods: This is a multicentre, retrospective cohort study analysing data from patients with HR+/HER2-low and HR+/HER2-0 MBC treated with CDK4/6i as first-line or second-line therapy at the Oncology Units of IRCCS San Matteo Hospital and ICS Maugeri IRCCS in Pavia, Italy, from January 2017 to October 2023. The aim was to assess the activity and effectiveness of CDK4/6i in a real-life setting. Results: Of the 241 patients included, 240 (99.6%) were women. The median age at diagnosis was 57 years (IQR 48–65 years). Most patients had pM M0 (70.5%). At presentation, 112 (46.5%) had HER2-low and 129 (53.5%) had HER2-0 status. CDK4/6i were administered as first-line therapy in 89.2% of patients and as second-line therapy in 10.8% of patients, with palbociclib (61.4%) being the most common. The median progression-free survival during CDK4/6i therapy was 36.3 months (95% CI 23.6 months to not reached), while the median overall survival was 60.5 months (95% CI 54.4 months to not reached). Progression-free survival differed significantly between palbociclib and abemaciclib/ribociclib (24.4 versus 53.7 months; p=0.0109) and between first-line and second-line therapy (40.5 versus 21.2 months; p=0.0466). Conclusion: CDK4/6i are effective in both HER2-low and HER2-0 MBC, with HER2-low potentially benefiting more from first-line therapy.https://www.drugsincontext.com/patterns-of-treatment-and-outcomes-of-patients-with-metastatic-her2-low-breast-cancer-treated-with-cdk4-6-inhibitors-and-hormone-therapy/abemaciclibantibody–drug conjugatesher2-lowmetastatic breast cancerpalbociclibribociclibtherapeutic strategies |
| spellingShingle | Federico Sottotetti Barbara Tagliaferri Gianpiero Rizzo Raffaella Palumbo Giulia Chessa Chiara Raso Lorenzo Perrone Alberto Malovini Valentina Tibollo Laura Deborah Locati Paolo Pedrazzoli Angioletta Lasagna Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy Drugs in Context abemaciclib antibody–drug conjugates her2-low metastatic breast cancer palbociclib ribociclib therapeutic strategies |
| title | Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy |
| title_full | Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy |
| title_fullStr | Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy |
| title_full_unstemmed | Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy |
| title_short | Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy |
| title_sort | patterns of treatment and outcomes of patients with metastatic her2 low breast cancer treated with cdk4 6 inhibitors and hormone therapy |
| topic | abemaciclib antibody–drug conjugates her2-low metastatic breast cancer palbociclib ribociclib therapeutic strategies |
| url | https://www.drugsincontext.com/patterns-of-treatment-and-outcomes-of-patients-with-metastatic-her2-low-breast-cancer-treated-with-cdk4-6-inhibitors-and-hormone-therapy/ |
| work_keys_str_mv | AT federicosottotetti patternsoftreatmentandoutcomesofpatientswithmetastaticher2lowbreastcancertreatedwithcdk46inhibitorsandhormonetherapy AT barbaratagliaferri patternsoftreatmentandoutcomesofpatientswithmetastaticher2lowbreastcancertreatedwithcdk46inhibitorsandhormonetherapy AT gianpierorizzo patternsoftreatmentandoutcomesofpatientswithmetastaticher2lowbreastcancertreatedwithcdk46inhibitorsandhormonetherapy AT raffaellapalumbo patternsoftreatmentandoutcomesofpatientswithmetastaticher2lowbreastcancertreatedwithcdk46inhibitorsandhormonetherapy AT giuliachessa patternsoftreatmentandoutcomesofpatientswithmetastaticher2lowbreastcancertreatedwithcdk46inhibitorsandhormonetherapy AT chiararaso patternsoftreatmentandoutcomesofpatientswithmetastaticher2lowbreastcancertreatedwithcdk46inhibitorsandhormonetherapy AT lorenzoperrone patternsoftreatmentandoutcomesofpatientswithmetastaticher2lowbreastcancertreatedwithcdk46inhibitorsandhormonetherapy AT albertomalovini patternsoftreatmentandoutcomesofpatientswithmetastaticher2lowbreastcancertreatedwithcdk46inhibitorsandhormonetherapy AT valentinatibollo patternsoftreatmentandoutcomesofpatientswithmetastaticher2lowbreastcancertreatedwithcdk46inhibitorsandhormonetherapy AT lauradeborahlocati patternsoftreatmentandoutcomesofpatientswithmetastaticher2lowbreastcancertreatedwithcdk46inhibitorsandhormonetherapy AT paolopedrazzoli patternsoftreatmentandoutcomesofpatientswithmetastaticher2lowbreastcancertreatedwithcdk46inhibitorsandhormonetherapy AT angiolettalasagna patternsoftreatmentandoutcomesofpatientswithmetastaticher2lowbreastcancertreatedwithcdk46inhibitorsandhormonetherapy |